Acta Med. 2003, 46: 215-216
https://doi.org/10.14712/18059694.2019.37
Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
References
1. F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053–63.
2. K, Kiura K, Ueoka H et al. Dramatic effect of ZD1839 (‘Iressa’) in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 2003; 40:73–6.
<https://doi.org/10.1016/S0169-5002(03)00028-X>
3. M, Yano S, Giaccone G et al. Final results from a phase II trial of ZD1839 (‘Iressa’) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002; 22:298a.
4. A, Saijo Y, Maemondo M et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361:137–9.
<https://doi.org/10.1016/S0140-6736(03)12190-3>
5. MG, Natale RB, Herbst RS et al. A phase II trial of ZD1839(‘Iressa’) in advanced non-small cell lung cancer(NSCLC) patients who had failed platinumand docetaxel-based regimens(IDEAL 2). Proc Am Soc Clin Oncol 2002; 22: 292a.
6. JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD1839(Iressa) in the brain. Ann Oncol 2003; 14:656–8.
<https://doi.org/10.1093/annonc/mdg153>
